Dr. Beckermann on Investigational Treatment Strategies in mRCC
In Partnership With:
Kathryn E. Beckermann, MD, PhD, discusses investigational treatment strategies in metastatic renal cell carcinoma.
Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses investigational treatment strategies in metastatic renal cell carcinoma (mRCC).
VEGF inhibitors and mTOR inhibitors are used to target VHL loss, says Beckermann. Given the success of these agents, investigators are searching for other targets in the pathway.
Additionally, combinations of PD-1 and CTLA-4 inhibitors, and PD-1/PD-L1 and VEGF inhibitors have shown improved response rates in patients with mRCC, explains Beckermann.
Triplet regimens are being explored to determine whether overall responses and disease control can be improved without sacrificing the tolerability and safety of treatment, concludes Beckermann.
